Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Diamminedichloroplatinum
Drug ID BADD_D00643
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 441203
TTD Drug ID D08ZRW
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula Cl2H6N2Pt+2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt+2]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Leukoencephalopathy17.13.02.003--
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.003--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity17.02.10.002; 12.03.01.011--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.002--Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Ototoxicity04.03.01.004; 12.03.01.012--Not Available
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Papilloedema24.03.07.001; 17.07.02.004; 06.09.02.002--
Paraesthesia17.02.06.005; 23.03.03.094--
Phlebitis24.12.03.004; 12.02.01.002--
Polyuria20.02.03.002--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages